Interview with Patrik De Haes, Chief Executive Officer, ThromboGenics
24.01.2013
Related Interviews
Mark Dekker – General Manager Benelux, Astellas Pharma
20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets –…
Margit Kunz – Chief Executive Director, AHK Debelux
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Marnix Denys – Managing Director, beMedTech
Marnix Denys of beMedTech – the Belgian association for the medical technology industry – outlines the agenda priorities for the organisation that he hopes will lead to a more value-driven…
Opinion / How Can the Generics Industry Up its Game on Essential Medicine Access?
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
Leadership / Bill Sibold Swaps Sanofi for Biotech Seeking First NASH FDA Approval
After a 12-year stint at Sanofi, Bill Sibold is leaving Big Pharma to join the Pennsylvania-based biotech Madrigal Pharmaceuticals as CEO. Sibold, no stranger to ground-breaking launches, having brought the…
MEA / Clinical Research in the UAE: Quickfire Progress & The Road Left to Travel
With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and…
